8-K: ResMed Q1 FY26 Revenue Jumps 9%, Boosted by Strong Margins

ResMed Inc. reports a strong start to fiscal year 2026 with a 9% revenue increase and significant gross margin expansion, alongside a declared quarterly dividend.

Summary

• Revenue for the first quarter of fiscal year 2026 increased by 9% to $1.3 billion, or 8% on a constant currency basis, compared to the prior year period.
• Gross margin improved by 290 basis points to 61.5%, with non-GAAP gross margin up 280 basis points to 62.0%.
• Income from operations increased by 15%, and non-GAAP income from operations rose by 19%.
• Diluted earnings per share (EPS) grew by 12% to $2.37, while non-GAAP diluted EPS increased by 16% to $2.55.
• Operating cash flow for the quarter was $457 million.
• The board of directors declared a quarterly cash dividend of US $0.60 per share, payable on December 18, 2025, to shareholders of record on November 13, 2025.
• The company repurchased 523,000 shares for $150 million as part of its capital management strategy.
• Restructuring-related charges of $16 million were recorded due to company-wide workforce planning activities.

Sentiment

Score: 8

Explanation: The company reported strong financial performance across key metrics, including revenue growth, significant margin expansion, and double-digit EPS growth. Management's commentary is highly positive, emphasizing strategic success and future growth. Shareholder returns through dividends and buybacks further contribute to a positive sentiment, despite minor restructuring charges.

Positives

• Strong revenue growth of 9% (8% constant currency) to $1.3 billion, indicating robust demand for products.
• Significant gross margin expansion of 290 basis points (280 bps non-GAAP) to 61.5%, driven by manufacturing efficiencies and component cost improvements.
• Double-digit growth in income from operations (15% GAAP, 19% non-GAAP) and diluted EPS (12% GAAP, 16% non-GAAP), demonstrating improved profitability.
• Healthy operating cash flow of $457 million, providing strong liquidity.
• Continued shareholder returns through a declared quarterly cash dividend of $0.60 per share and $150 million in share repurchases.
• Publication of a landmark study projecting a significant increase in U.S. adults with OSA by 2050, highlighting a growing market opportunity.
• Received dual Red Dot Product Design 2025 awards for the AirTouch N30i, reinforcing product innovation and patient-centered design.
• Launch of the Sleep Institute, a global initiative to elevate sleep health as a public health priority.

Negatives

• Recorded $16 million in restructuring-related charges due to workforce planning activities, impacting GAAP income from operations.

Risks

• The safe harbor statement indicates that forward-looking statements are subject to risks and uncertainties that could cause actual results to materially differ, and refers to ResMed's periodic reports on file with the U.S. Securities & Exchange Commission for additional risks.

Future Outlook

Management remains committed to ongoing operational excellence and strategic investment in innovation throughout fiscal year 2026, aiming to deliver strong, sustainable, profitable growth by expanding access to life-changing healthcare solutions globally. The company's strategy focuses on transforming healthcare in the home with hardware, software, and solutions.

Management Comments

• "Our fiscal year 2026 is off to a strong start, with first-quarter performance reflecting continued progress toward our mission of helping people sleep better, breathe better and live longer and healthier, with care provided in their own home."
• "We delivered 9% headline revenue growth year-over-year, with a very strong 280 basis points of non-GAAP gross margin expansion, resulting in double-digit bottom-line performance: 16% non-GAAP EPS growth."
• "These results reinforce the success of our strategy to transform healthcare in the home with hardware, software and solutions that people love."
• "As we advance through fiscal year 2026, we remain committed to ongoing operational excellence and strategic investment in innovation, ultimately delivering strong, sustainable, profitable growth as we provide access to life-changing care for the billions of people worldwide who need our market-leading healthcare solutions delivered right where they live."

Industry Context

The announcement highlights a significant and growing market for sleep and respiratory care, with a landmark study projecting a 35% relative increase in U.S. adults with Obstructive Sleep Apnea (OSA) by 2050. This underscores the increasing demand for ResMed's core products and services. The company's focus on 'healthcare in the home' aligns with broader industry trends towards decentralized care models and digital health solutions, positioning it well within a growing and evolving healthcare landscape.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess against global benchmarks.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, increased earnings, declared quarterly dividend of $0.60 per share, and share repurchase program.
• Employees: Impacted by restructuring-related charges following company-wide workforce planning activities, which included employee severance and termination benefits.
• Customers: Benefit from continued innovation, as evidenced by Red Dot Product Design awards and the launch of the Sleep Institute, aiming to provide better and more accessible healthcare solutions.
• Investment Professionals: Provided with detailed financial results and management commentary for analysis and decision-making.

Next Steps

• Continue operational excellence and strategic investment in innovation throughout fiscal year 2026.
• Provide access to life-changing care for people worldwide needing market-leading healthcare solutions.
• Hold a webcast and conference call on October 30, 2025, to discuss Q1 FY26 results.
• Pay quarterly cash dividend on December 18, 2025.

Key Dates

Recommendation

ResMed's Q1 FY26 results demonstrate exceptional financial health and operational efficiency, with robust revenue growth, significant gross margin expansion, and double-digit increases in both income from operations and EPS. The company's strategic focus on 'healthcare in the home' aligns with favorable industry trends, particularly the projected increase in OSA prevalence. Consistent shareholder returns through dividends and share buybacks, coupled with ongoing innovation and positive management outlook, suggest strong future performance. The minor restructuring charges are a one-time event and do not detract from the overall positive trajectory. These factors collectively indicate a compelling investment opportunity.

Keywords

ResMed, RMD, Earnings, Q1 2026, Financial Results, Sleep Apnea, Respiratory Care, Medical Devices, Healthcare Technology, Dividends, Share Repurchase, Gross Margin, EPS, Operating Cash Flow